Back to the main directory
Event / Equity
- Espresso | Commerzbank | Reduce | The DB merger is offso what next? by Kepler Cheuvreux
- Espresso | Econocom | Hold | Unexciting Q1 sales release by Kepler Cheuvreux
- Espresso | Casino | Hold | Q1 sales as weak as expected by Kepler Cheuvreux
- Espresso | Aena | Buy | Upward revision of traffic guidance by Kepler Cheuvreux
- Espresso | BE Semiconductor | Hold | Bottoming out, but recovery may take time to unfold by Kepler Cheuvreux
- Espresso | Wereldhave | Buy | Still challenging, as expected by Kepler Cheuvreux
- Espresso | Manitou | Buy | Strong Q1 FY guidance confirmed by Kepler Cheuvreux
- Espresso | Saab | Buy | Q1 first glance: neutral to slightly positive report, unchanged outlook by Kepler Cheuvreux
- Espresso | Technicolor | Hold | Q1 trading commentary: flat revenues, further opex/capex efforts by Kepler Cheuvreux
- Espresso | Schindler | Buy | Solid growth, but EBIT margin below consensus in Q1 - guidance reiterated by Kepler Cheuvreux
- Espresso | Electrolux | Buy | First glance Q1 - Good by Kepler Cheuvreux
- Espresso | Intrum | Buy | Adjusted EBIT miss of 3% by Kepler Cheuvreux
- Espresso | Sioen | Buy | Solid Q1, but not immune to the slowdown by Kepler Cheuvreux
- Espresso | TechnipFMC | Buy | Strong BtB (2.2x), but weak results by Kepler Cheuvreux
- Espresso | Skanska | Buy | Q1: weak but not as bad as headlines suggest by Kepler Cheuvreux
- Espresso | Sopra steria | Hold | Good start to the year by Kepler Cheuvreux
- Espresso | Capgemini | Buy | 5% organic growth in Q1 by Kepler Cheuvreux
- Espresso | Safran | Buy | Acing Q1 consensus expectations by Kepler Cheuvreux
- Espresso | Eurofins | Reduce | Forex to the rescue by Kepler Cheuvreux
- Espresso | SES | Hold | Q1 2019 results review by Kepler Cheuvreux
- Espresso | Neste | Buy | Q1: overall in line, Renewable continues to beat by Kepler Cheuvreux
- Espresso | Aker BP | Hold | Weak EPS in Q1 strong cash flow by Kepler Cheuvreux
- Espresso | Pandox | Buy | Q1: outlook still calls for RevPar growth in 2019E by Kepler Cheuvreux
- Espresso | AstraZeneca | Buy | Excellent 14% sales growth, driven by older drugs and emerging markets by Kepler Cheuvreux
- Espresso | Signify | Hold | Q1 margin in line with consensus, FCF guidance confirmed by Kepler Cheuvreux